Literature DB >> 33388439

Hydrogel-Based Colorectal Cancer Organoid Co-Culture Models.

Xiaobei Luo1, Eliza Li Shan Fong2, Chaojun Zhu3, Quy Xiao Xuan Lin4, Man Xiong5, Aimin Li3, Tingting Li6, Touati Benoukraf7, Hanry Yu8, Side Liu3.   

Abstract

The lack of cancer-associated fibroblasts (CAFs) in patient-derived organoid (PDO) models is a major limitation as CAFs contribute to tumor progression and drug resistance. In the present study, we addressed this problem by establishing in vitro conditions that enable the co-culture of colorectal cancer (CRC) PDO with patient-derived CAFs. Considering that the CRC extracellular matrix is high in hyaluronan and collagen I, we hypothesized that hyaluronan-gelatin hydrogels may serve as a suitable alternative 3D matrix to traditionally used basement membrane extracts to support the co-culture of CRC PDO and CAFs. We report the development of in vitro models consisting of CRC PDO encapsulated within a well-defined three-dimensional (3D) hyaluronan-gelatin hydrogel and co-cultured with patient-derived CAFs. Through RNA- and whole-exome sequencing, we first show that these hydrogels are capable of maintaining key molecular characteristics of the original patient tumors in CRC PDO but not support the culture of CAFs. Further, based on our findings that CRC PDO culture medium poorly supports CAF viability, we developed a co-culture strategy that maintains the viability of both CRC PDO and CAFs. We found that even in the absence of growth factors conventionally used to support CRC PDO culture, CAFs were able to maintain the proliferation of the cultured CRC PDO in the hydrogels and restore distinct biological pathways absent in the PDO culture alone but present in patient tissues. Lastly, we demonstrate that these CRC PDO-CAFs co-culture models are suitable for evaluating standard-of-care drugs, making them potentially very useful for realizing personalized cancer medicine.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer-associated fibroblasts; Colorectal cancer; Organoids; Stroma

Year:  2020        PMID: 33388439     DOI: 10.1016/j.actbio.2020.12.037

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  6 in total

Review 1.  Programming hydrogels to probe spatiotemporal cell biology.

Authors:  Taimoor H Qazi; Michael R Blatchley; Matthew D Davidson; F Max Yavitt; Megan E Cooke; Kristi S Anseth; Jason A Burdick
Journal:  Cell Stem Cell       Date:  2022-04-11       Impact factor: 25.269

2.  Culture of patient-derived multicellular clusters in suspended hydrogel capsules for pre-clinical personalized drug screening.

Authors:  Haijiang Dong; Zequn Li; Suchen Bian; Guangyuan Song; Wenfeng Song; Mingqi Zhang; Haiyang Xie; Shusen Zheng; Xuxu Yang; Tiefeng Li; Penghong Song
Journal:  Bioact Mater       Date:  2022-03-19

Review 3.  Patient-derived rectal cancer organoids-applications in basic and translational cancer research.

Authors:  Yumeng Yan; Io Hong Cheong; Peizhan Chen; Xiaoguang Li; Xianli Wang; Hui Wang
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

Review 4.  The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers.

Authors:  Ya-Ya Yu; Yan-Juan Zhu; Zhen-Zhen Xiao; Ya-Dong Chen; Xue-Song Chang; Yi-Hong Liu; Qing Tang; Hai-Bo Zhang
Journal:  Biomark Res       Date:  2022-10-08

5.  Porcine Decellularized Diaphragm Hydrogel: A New Option for Skeletal Muscle Malformations.

Authors:  Daniele Boso; Eugenia Carraro; Edoardo Maghin; Silvia Todros; Arben Dedja; Monica Giomo; Nicola Elvassore; Paolo De Coppi; Piero Giovanni Pavan; Martina Piccoli
Journal:  Biomedicines       Date:  2021-06-22

Review 6.  Decellularized Colorectal Cancer Matrices as Bioactive Scaffolds for Studying Tumor-Stroma Interactions.

Authors:  Ângela Marques-Magalhães; Tânia Cruz; Ângela Margarida Costa; Diogo Estêvão; Elisabete Rios; Pedro Amoroso Canão; Sérgia Velho; Fátima Carneiro; Maria José Oliveira; Ana Patrícia Cardoso
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.